Using propofol to improve sleep and reduce depression in older adults
Official title: Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II
Run by Washington University School of Medicine · NCT06867549 · Data updated 2026-11-12
This study is testing if using propofol to improve sleep, along with short therapy sessions, can help older adults feel less depressed.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 60 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 1 site (St Louis, Missouri) |
| Status | Recruiting |
| Started | March 4, 2025 |
| Main results expected | April 1, 2028 |
| Study ends | May 1, 2028 |
| Registry record updated | August 27, 2026 |
| Trial ID | NCT06867549 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are English-speaking adults aged 60 and older who have depression that has not responded to at least one adequate trial of oral antidepressants.
✕Probably not a fit
Patients with significant heart conditions, prior adverse reactions to propofol, or those currently undergoing other intensive treatments for depression may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effects of targeted propofol infusion combined with brief behavioral therapy on sleep and depression in geriatric patients. The study will enroll 70 participants who will receive either low or moderate doses of propofol to enhance slow wave sleep, with EEG monitoring to assess brain activity. Participants will also undergo several sessions of Brief Behavioral Therapy for Insomnia to support their treatment. The goal is to determine if improving sleep can lead to better clinical and cognitive outcomes for older adults suffering from depression.
Why it matters
Potential benefit: If successful, this approach could provide a novel treatment option for older adults with treatment-resistant depression by improving their sleep quality and overall mental health.
How similar studies have gone: While the approach of using propofol in this context is innovative, similar studies targeting sleep disturbances in depression have shown promise, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Age 60 or greater * English speaking (as an interpreter will not be readily available should a participant need to convey any safety concerns during the propofol infusion sessions or require guidance on conducting at-home sleep recordings) * Depression (non-responsive to at least one adequate trial of oral antidepressants for current episode). Exclusion Criteria: * Presence of symptomatic coronary artery disease * Presence of marked congestive heart failure/cardiomyopathy(NYHA \> Class III, LVEF \<40%, greater than mild RV systolic dysfunction) * Prior reaction to propofol * Resting heart rate \< 50 bpm * Treatment with Electroconvulsive therapy/Transcranial Magnetic Stimulation/vagal nerve stimulation within 6 weeks * Body mass index \> 35 * C-SSRS of 4 or greater (active suicidal ideation with some intent and with/without a specific plan) * MoCA score \< 23 (at least mild dementia) * Schizophrenia * Bipolar disorder * Non-prescribed use of amphetamines, opioids, cocaine, or phencyclidine; Urine THC \> 150 ng/ml * Intake of \> 14 beers/week (or equivalent) * Anesthetic exposure in the past 4 weeks * Concurrent use of benzodiazepines \> 2 mg/day lorazepam or equivalent, trazodone \> 50 mg/day, or gabapentin \> 600mg/day.
Where it's running
-
Washington University School of Medicine/Barnes-Jewish Hospital
St Louis, Missouri, United States Recruiting
Study contacts
- Principal investigator: Ben Palanca, MD PhD — Washington University School of Medicine
- Study coordinator: Sarah E Knarr
- Email: knarr.sarah@wustl.edu
- Phone: 314-362-2415
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Smartphone-supported single-session psychotherapy for postpartum depression
A single online therapy session plus four weeks of app-based support is being tested to see if it reduces depressive symptoms in postpartum women compared with a waitlist.
-
Mindful Smartphone Use: A Mindfulness-Based Program for Teens with Sleep and Mood Challenges
This study tests Mindwire, a mindfulness-based program, to see if it helps teens with problematic phone use who also have depression or anxiety.
-
Tele-based wellbeing centres for women's mental health in Bangladesh
A randomized trial tests whether tele-counselling for depression and anxiety in Bangladeshi women is as effective as in-person counselling.
-
Remote monitoring for adults with depression using ThIA Suivi
This study tests whether adding the ThIA Suivi remote monitoring tool to usual psychiatric care helps adults with depression feel more improved after 3 months compared with standard care alone.
-
HBOT to see if it helps cognition and well‑being in first responders with prior brain injury
This study tests whether 40 hyperbaric oxygen therapy sessions can improve thinking skills and post-concussion symptoms in current or former first responders with a history of brain injury.
-
Focused ultrasound for mood and anxiety disorders
This study tests whether repeated low-intensity focused ultrasound using the ATTN201 device can help people with subsyndromal to moderate depression, anxiety, or OCD.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.